Market open
MiNK Therapeutics/$INKT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About MiNK Therapeutics
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
Ticker
$INKT
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
23
Website
INKT Metrics
BasicAdvanced
$33M
-
-$2.86
0.16
-
Price and volume
Market cap
$33M
Beta
0.16
52-week high
$13.79
52-week low
$4.56
Average daily volume
9.4K
Financial strength
Current ratio
0.717
Quick ratio
0.658
Long term debt to equity
-25.144
Total debt to equity
-25.144
Management effectiveness
Return on assets (TTM)
-137.35%
Return on equity (TTM)
57.30%
Valuation
Price to book
-1.67
Price to tangible book (TTM)
-1.67
Price to free cash flow (TTM)
-3.254
Growth
Earnings per share change (TTM)
-56.27%
3-year earnings per share growth (CAGR)
-37.32%
INKT News
AllArticlesVideos
MiNK Therapeutics, Inc. (INKT) Q4 2024 Earnings Call Transcript
Seeking Alpha·3 weeks ago
MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress
GlobeNewsWire·3 weeks ago
MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for MiNK Therapeutics stock?
MiNK Therapeutics (INKT) has a market cap of $33M as of April 08, 2025.
What is the P/E ratio for MiNK Therapeutics stock?
The price to earnings (P/E) ratio for MiNK Therapeutics (INKT) stock is 0 as of April 08, 2025.
Does MiNK Therapeutics stock pay dividends?
No, MiNK Therapeutics (INKT) stock does not pay dividends to its shareholders as of April 08, 2025.
When is the next MiNK Therapeutics dividend payment date?
MiNK Therapeutics (INKT) stock does not pay dividends to its shareholders.
What is the beta indicator for MiNK Therapeutics?
MiNK Therapeutics (INKT) has a beta rating of 0.16. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.